OMICRON has caused global concern over signs that it can transmit faster than previous strains and fears that its multiple mutations could help it evade immune defences provided by vaccines. No deaths have so far been associated with the variant.
In preliminary results published on Wednesday, Pfizer and BioNTech said their vaccine "is still effective in preventing Covid-19, also against Omicron, if it has been administered three times".
But they warned that "the Omicron variant is probably not sufficiently neutralised after two doses".
According to early laboratory research using blood serum from vaccinated people, a booster third dose generated around the same level of antibodies against Omicron as is seen after a second dose with the initial strain.
Blood samples from people who had received two doses of the current vaccine showed on average a 25-fold reduction in neutralising antibodies compared to the early strain of the virus, the companies said.
But they added that another part of the immune response -- from T cells -- were probably still effective against the variant, adding that "vaccinated individuals may still be protected against severe forms of the disease".
Their results have not been peer reviewed.
- Real world test -
Speaking at a press conference, BioNTech CEO Ugur Sahin said that reducing the time required between second and third doses of the vaccine was the "right way to go" to increase protection through the winter.
The United Kingdom has begun giving booster shots to individuals at least three months after their second dose, while the delay to receive an additional shot is longer elsewhere.
The vaccine-makers said that an Omicron-specific version of the jab, currently in development by BioNTech, would be ready for delivery by March, pending regulatory approval.
The decision to switch production to the tailored vaccine would depend "on the spread of the Omicron variant", the German company's chief operating officer Sierk Poetting said at a press conference.
The announcement comes after other preliminary results from a small study in South Africa suggested there was up to a forty-fold drop in the ability of the antibodies from the Pfizer-BioNTech vaccine to neutralise Omicron, compared to an early strain.
The results suggest "that there is definitely much less neutralisation against Omicron compared to neutralisation against the original strains that came out of Wuhan initially," said Willem Hanekom, executive director of the Africa Health Research Institute, which carried out the study.
But he cautioned that it was important to be "extraordinarily careful" interpreting the results because they only reflect a laboratory setting.
"What we need is real world results of what is happening out there," he told AFP.
- Emerging evidence -
Omicron counts more than 30 mutations on the spike protein that dots the surface of the coronavirus and allows it to invade cells.
Given the array of changes in this strain of the virus, Paul Moss, Deputy Head of the College of Medical and Dental Sciences at the University of Birmingham, said this kind of result "was not unexpected".
However he said "emerging evidence from booster vaccinations shows that they are capable of generating very high levels of antibody which should potentially still provide valuable protection against infection".
The detection of the first Omicron cases two weeks ago coincided with soaring infection numbers across the world, and the variant added fuel to concerns about a global Covid resurgence.
Dozens of nations have re-imposed border restrictions in response to the spread of the new virus variant and raised the possibility of a return of economically punishing lockdowns.
Omicron has so far been found in 57 countries, the WHO said.
ETX Studio
Sat Dec 11 2021
Omicron counts more than 30 mutations on the spike protein that dots the surface of the coronavirus and allows it to invade cells. - REUTERS
Isu samun: Terengganu pandang serius kejadian melanda Akhyar Rashid
Akhyar Rashid mengalami kecederaan ringan di bahagian kepala dan kaki, namun beliau dilaporkan berada di dalam keadaan stabil.
Permohonan pembatalan kes rasuah Guan Eng, isteri dan Li Koon ditolak
Permohonan itu membabitkan projek asrama pekerja asing bernilai RM11.6 juta.
WEF: Mendasari geopolitik, mencari keterangkuman
Editor Kanan Niaga AWANI, Najib Aroff membawakan rangkuman Mesyuarat Khas WEF yang berlangsung baru-baru ini di Riyadh, Arab Saudi bersama Pengarah Strategi, KRA Group, Amir Fareed Rahim.
EPL: Mauricio Pochettino pimpin Chelsea benam Spurs
Satu gol pada setiap separuh masa daripada Trevoh Chalobah dan Nicolas Jackson memberikan The Blues kemenangan yang tidak ternilai.
Kadar Fed AS kekal, ekonomi akan mengukuh atau melemah?
Rizab Persekutuan (Fed) AS mengekalkan kadar faedah penanda arasnya tidak berubah. Apakah faktor yang menyumbang kepada keputusan ini dan bagaimana prospek ekonomi serta pasaran dalam tempoh terdekat?
Pelaburan Microsoft: Memperkasa era baharu AI di Malaysia
Microsoft telah mengumumkan komitmen terbesar dalam sejarah 32 tahunnya di negara ini dengan pelaburan berjumlah US$2.2 bilion dalam tempoh empat tahun akan datang untuk menyokong transformasi digital Malaysia. Bagaimana untuk manfaatkan pelaburan ini serta mempekasa era baharu kecerdasan buatan (AI) di Malaysia?
'Pindahkan jasad Maradona ke tempat lebih selamat' - Anak
Anak-anak Maradona fail permintaan kepada mahkamah untuk pindahkan jasad legenda bola sepak dunia itu "ke tempat yang lebih selamat."
KPDN serbu premis jual produk berlabel 'No Palm Oil'
Kesemua produk aiskrim terbabit telah disita untuk siasatan lanjut dengan nilai rampasan berjumlah RM897.60.
FAM penuhi permintaan Pan-gon
Permintaan Kim Pan-gon yang mahu penerbangan sewa khas untuk ke Kyrgyzstan juga telah ditunaikan oleh FAM.
Cuaca panas dunia bakal cecah suhu ekstrem
El Nino akan mendorong kurangnya hujan dan berlakunya episod kemarau yang lebih teruk daripada biasa.
COVID-19 terkawal tetapi virus akan terus ada bersama kita - KKM
Kebanyakan kes COVID-19 yang dilaporkan mengalami gejala ringan dan tidak memerlukan rawatan di hospital.
COVID-19: Kes aktif varian Omicron bergejala ringan - Pakar perubatan
Beliau berkata kes COVID-19 dijangka berkurangan selepas satu bulan berdasarkan pemerhatian trend jangkitan virus oleh KKM.
COVID-19: Kes meningkat kepada 12,757 pada ME49/2023
Walaupun terdapat peningkatan kes COVID-19, keadaan di Malaysia masih terkawal dan tidak membebankan fasiliti kesihatan sedia ada.
COVID-19: Kes jangkitan meningkat kepada 2,305 minggu lalu, 21 varian Omicron
Daripada jumlah itu, terdapat 20 kes Variant of Concern (VOC) dan satu kes Variant of Interest (VOI).
COVID-19: Qatar kesan kes pertama varian baharu EG.5
Qatar mengesan kes pertama varian baharu COVID-19 dikenali EG.5 di negara itu, kata Kementerian Kesihatan Awam pada Khamis.
Saintis seru rakyat UK pakai pelitup muka ekoran varian baharu "Eris"
Saintis menggesa orang ramai di United Kingdom kembali memakai pelitup muka di tengah-tengah kebimbangan "mutasi" subvarian Omicron, "Eris" yang kini menyumbang satu daripada 10 kes di negara itu.
Berita antarabangsa pilihan sepanjang hari ini
Antara pelbagai berita luar negara yang disiarkan di Astro AWANI, berikut adalah yang paling menjadi tumpuan sepanjang Selasa, 18 April 2023.
COVID-19: Indonesia kesan tujuh kes Arcturus setakat ini
Indonesia mengesan lima kes baharu subvarian Omicron, Arcturus, menjadikan jumlah keseluruhan kepada tujuh kes setakat semalam.
Kes COVID-19 dalam negara masih terkawal - Dr Zaliha
Kes COVID-19 di dalam negara ini masih lagi terkawal meskipun berlaku sedikit peningkatan kebelakangan ini dan rakyat tidak perlu panik, kata Menteri Kesihatan Dr Zaliha Mustafa.
Vaksin COVID-19: Australia lancar dos penggalak kelima
Keputusan itu memperluaskan kelayakan suntikan dos penggalak merangkumi kira-kira 14 juta orang yang akan ditawarkan vaksin.